Abstract 382P
Background
The tribal populations throughout India have remained socially and culturally alienated from mainstream Indian society until developmental and conservation activities in tribal areas forced interactions between them. The precancerous oral lesion is a major public health problem among South Indian tribes in Kerala state. The aim of this study was to explore oral health disparities among the underprivileged Paniya and the privileged Kurichiya tribes of Wayanad, South India from the Precancerous oral lesions perspective.
Methods
A cross sectional survey was done among 600 Kurichiya tribes and 400 Paniya tribal populations of Wayanad District, India from January 2013 to June 2013 after approval from the Institutional ethical committee. A pretested structured questionnaire was used to collect data regarding study variables. Oral health survey form was used to record the oromucosal status of the study population after obtaining informed consent.
Results
In this study Precancerous oral lesions was found to be far more prevalent among the underprivileged Paniya tribes than among the privileged Kurichiya tribes (P < 0.0001). The prevalence of leukoplakia was found to be 42% amongst the Paniya tribes. This was much higher than the 2% found among the Kurichiya tribes. Among the Paniya tribes a statistically significant relationship was observed between Precancerous oral lesions and poor access to oral health care (P < 0.001).
Conclusions
The Paniya tribe is a distinct community with their own cultural beliefs, habits, and attitudes. High prevalence of precancerous oral lesions in the underprivileged population was due to tobacco usage and alcohol consumption and lack of awareness regarding the deleterious effects of the products used. Knowledge of these differences can be used to provide appropriate health education programs suitably targeted to reduce the use of the known risk factors for oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract